GEHC vs MDT Stock Comparison: AI Score, Valuation, Performance and Upside
GE HealthCare and Medtronic both operate in medical technology, but GE HealthCare concentrates on diagnostic imaging, ultrasound, and patient monitoring as a recently spun-off standalone company, while Medtronic operates a much broader, longer-established portfolio spanning cardiac, neuroscience, surgical, and diabetes device categories.
GE HealthCare offers focused exposure to diagnostic imaging and AI-enabled healthcare technology as an independent company, while Medtronic offers exposure to a larger, more diversified global medical device portfolio. Consider whether you prefer GE HealthCare's focused imaging and AI positioning or Medtronic's diversified device scale.
MDT holds the edge across 3 of 5 key metrics in this comparison. MDT has delivered stronger 1-year price return (+9.62% vs +8.31%), though GEHC has the better forward P/E setup (13.26x vs 14.24x for MDT). MDT leads on both revenue growth (9.90%) and operating margin (22.05%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for GEHC (+15.02%) than for MDT (+8.34%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want focused exposure to diagnostic imaging, ultrasound, and patient monitoring technology
- Believe growing AI integration into imaging and diagnostics will drive next-generation demand
- Value the more concentrated management focus possible following the spin-off from General Electric
- Are comfortable with the company still establishing its independent track record as a standalone public company
- Want exposure to a highly diversified global medical device portfolio spanning cardiac, neuroscience, surgical, and diabetes categories
- Value the scale and research and development resources of one of the largest medical device companies
- Believe established hospital relationships worldwide support consistent long-term product demand
- Prefer a longer-established, diversified device business over a recently independent, more focused company
| Metric | GEHC | MDT |
|---|---|---|
| AI scorei | 32.6 | 42.2 |
| AI ranki | #2121 | #1218 |
| Latest closei | $80.66 | $98.88 |
| 1M returni | +25.46% | +14.47% |
| 3M returni | +14.80% | +14.71% |
| 6M returni | +32.14% | +27.11% |
| 1Y returni | +8.31% | +9.62% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | GEHC | MDT |
|---|---|---|
| 1Y ago | $10.86K (+8.6%) started 2025-11-04 | $10.94K (+9.4%) started 2025-11-04 |
| 5Y ago | $13.54K (+35.4%) started 2022-12-15 | $10.11K (+1.1%) started 2021-11-05 |
| 10Y ago | $13.54K (+35.4%) started 2022-12-15 | $18.57K (+85.7%) started 2016-11-07 |
Hypothetical — past performance does not guarantee future results.
| Metric | GEHC | MDT |
|---|---|---|
| Market capi | $32.4B | $116.77B |
| Trailing P/Ei | 16.53 | 24.46 |
| Forward P/Ei | 13.26 | 14.24 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 1.93 | 3.78 |
| Analyst targeti | $82.50 | $98.84 |
| Target upsidei | +15.02% | +8.34% |
| Metric | GEHC | MDT |
|---|---|---|
| Revenue growthi | 5.80% | 9.90% |
| Earnings growthi | 16.80% | 18.30% |
| EPS growthi | +16.80% | +18.30% |
| FCF margini | +7.40% | +12.72% |
| Operating margini | 14.98% | 22.05% |
| Profit margini | 9.33% | 13.20% |
| ROIC proxyi | 19.38% | 9.84% |
| Return on equityi | 19.38% | 9.84% |
| Dividend yieldi | 0.20% | 3.16% |
| Payout ratioi | 2.96% | 70.02% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.82 | 0.57 |
| Debt/equityi | 93.97 | 58.21 |
| Current ratioi | 1.26 | 2.13 |
| Quick ratioi | 0.83 | 1.36 |
Over the past year, GEHC and MDT have moved moderately in the same direction (correlation of 0.42), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | GEHC | MDT |
|---|---|---|---|
| 1Y | Growthi | +8.56% | +9.36% |
| CAGRi | +8.57% | +9.37% | |
| Volatilityi | 35.63% | 24.92% | |
| Sharpe ratioi | 0.29 | 0.31 | |
| Sortino ratioi | 0.42 | 0.47 | |
| Max drawdowni | 32.53% | 30.00% | |
| Current drawdowni | 8.51% | 6.14% | |
| Avg drawdowni | 17.12% | 13.88% | |
| Ulcer Indexi | 19.81% | 16.06% | |
| Max daily dropi | 13.16% | 5.11% | |
| Max wkly dropi | 16.66% | 7.05% | |
| 5Y | Growthi | +34.92% | -10.11% |
| CAGRi | +8.01% | -2.11% | |
| Volatilityi | 33.09% | 22.60% | |
| Sharpe ratioi | 0.27 | -0.18 | |
| Sortino ratioi | 0.38 | -0.25 | |
| Max drawdowni | 37.35% | 39.97% | |
| Current drawdowni | 13.95% | 10.14% | |
| Avg drawdowni | 15.62% | 22.58% | |
| Ulcer Indexi | 18.19% | 23.83% | |
| Max daily dropi | 15.96% | 7.26% | |
| Max wkly dropi | 26.17% | 11.81% | |
| 10Y | Growthi | +34.92% | +46.16% |
| CAGRi | +8.01% | +3.87% | |
| Volatilityi | 33.09% | 23.68% | |
| Sharpe ratioi | 0.27 | 0.09 | |
| Sortino ratioi | 0.38 | 0.13 | |
| Max drawdowni | 37.35% | 45.10% | |
| Current drawdowni | 13.95% | 17.82% | |
| Avg drawdowni | 15.62% | 17.90% | |
| Ulcer Indexi | 18.19% | 22.19% | |
| Max daily dropi | 15.96% | 12.82% | |
| Max wkly dropi | 26.17% | 19.36% |
| Category | GEHC | MDT |
|---|---|---|
| Company | GE HealthCare Technologies Inc. | Medtronic plc |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Core business | A medical technology company providing diagnostic imaging equipment, ultrasound systems, patient monitoring solutions, and pharmaceutical diagnostics to hospitals and healthcare providers worldwide. | A diversified global medical device company providing products across cardiac, neuroscience, medical surgical, and diabetes categories, serving hospitals and healthcare providers with a broad range of therapeutic technologies. |
| Investor focus | Imaging equipment order backlog and book-to-bill trends, AI-enabled diagnostic technology adoption, and margin performance following its spin-off from General Electric. | Cardiac and diabetes segment growth trends, new product launch execution, and overall revenue growth trajectory across diversified device categories. |
- Established leadership position in diagnostic imaging equipment provides deep hospital customer relationships and installed base
- Growing integration of artificial intelligence into imaging and diagnostic products positions the company for next-generation healthcare technology demand
- Focused medical technology portfolio following the spin-off allows more concentrated management attention than under the prior diversified conglomerate structure
- Highly diversified product portfolio spans cardiac, neuroscience, surgical, and diabetes categories, reducing reliance on any single device category
- Massive scale as one of the largest medical device companies provides broad distribution and research and development resources
- Established relationships with hospitals and healthcare systems worldwide support consistent product demand
- Diagnostic imaging equipment demand is sensitive to hospital capital spending cycles and budget conditions worldwide
- Operating as a standalone public company following the spin-off requires establishing an independent track record with investors
- Competitive medical imaging and diagnostics landscape includes several other large, well-resourced device makers
- Diversified portfolio scale can make it harder to sustain above-market growth rates across all segments simultaneously
- Competitive dynamics in cardiac and diabetes device categories include well-resourced specialized competitors
- Regulatory and product quality compliance across such a broad portfolio requires extensive ongoing investment
Compare more than two at a time
This page is a fixed writeup on GEHC and MDT. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside GEHC and MDT, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.